Aurora Cannabis reports Q4 2026 earnings: $321M revenue, 11% growth, and strategic market shifts. Explore future outlook and financial performance.

Key Takeaways

• Net revenue increased by 11% year-over-year to $321 million for fiscal year 2026, exceeding guidance by $8 million.
• Adjusted EBITDA rose by 32% year-over-year, reaching $54 million.
• International sales made up 55% of total net revenue, reflecting the company's expanding global footprint.
• Cash and cash equivalents totaled $165 million, with no debt, positioning the company for future investments.
• Management anticipates a reset year for fiscal year 2027, driven by lower reimbursements in Canada.

Financial Performance

Aurora Cannabis Inc. reported robust financial results for the fiscal year and fourth quarter ending March 31, 2026. The company achieved net revenue of $321 million, representing an 11% increase from the previous year and exceeding the top end of its guidance by $8 million. This growth was primarily driven by significant demand in the global medical cannabis sector, which saw a 14% increase in revenue.

Notably, the company's adjusted gross margin rose to 64%, fueled by operational efficiencies and investments in its value chain. Adjusted EBITDA for the year reached $54 million, marking a 32% increase year-over-year. Despite the challenges posed by a changing regulatory landscape, Aurora maintained one of the strongest balance sheets in the industry, ending the fiscal year with $165 million in cash and cash equivalents and no debt.

Strategic Initiatives

Aurora's strategic focus remains centered on its leadership in medical cannabis, especially as competition intensifies in the sector. The company has made several significant moves to streamline operations and enhance profitability:

• Market Exits: The company is strategically exiting lower-margin segments, including parts of the Canadian consumer market and its plant propagation business, to focus resources on higher-margin global medical cannabis opportunities.
• Acquisition of Safari Flower Co.: In April 2026, Aurora acquired Safari Flower Co. for approximately $26.5 million. This acquisition aims to enhance its EU GMP capacity and support growth in international markets.
• Diversification of Product Offerings: Aurora has expanded its medical cannabis portfolio across Canada, Europe, Australia, and New Zealand, launching new formats such as dried flower, pre-rolls, and edibles. This effort is designed to meet the growing demand from patients and prescribers for consistent and reliable products.

The company's proactive approach to enhancing its operational efficiencies and expanding its product lineup positions it well to navigate evolving market dynamics effectively.

Future Outlook

Looking ahead, management projects that fiscal year 2027 will serve as a reset year due to anticipated changes in the reimbursement landscape for Canadian medical cannabis. The expected 30% reduction in reimbursement rates, effective April 1, 2026, will have a noticeable impact on the top line and adjusted gross profit. However, Aurora remains optimistic about international growth, particularly in Germany and Poland, where demand for medical cannabis continues to rise.

Management expects total net revenue to decline but believes this will be partially offset by growth in international markets. Adjusted gross margins are anticipated to be in the mid to high 50s, reflecting the shift towards higher-margin international operations. The company plans to invest in expanding its EU GMP capacity and further enhancing its product offerings to capitalize on emerging opportunities.

“We have built one of the most attractive global medical cannabis growth platforms in the world, anchored by a sizable footprint in Canada, Europe, Australia, and New Zealand,” said Miguel Martin, CEO of Aurora.

In addition, Aurora is closely monitoring potential regulatory changes in the U.S. concerning cannabis rescheduling, which could open new avenues for expansion and partnerships. As one of Canada's largest exporters of GMP-manufactured medical cannabis, Aurora is well-positioned to leverage its operational, commercial, and regulatory expertise in emerging markets.

Closing Assessment

Aurora Cannabis Inc. has demonstrated resilience and strategic foresight amid a rapidly evolving industry landscape. With strong financial performance and significant investments in high-margin international markets, the company is well-equipped to navigate the challenges ahead. Although fiscal year 2027 may present hurdles due to regulatory changes, Aurora's proactive initiatives and commitment to medical cannabis leadership position it for future growth and sustained shareholder value.

This analysis is based on public earnings call materials and is not investment advice.